argenx

ISIN US04016X1019

 | 

WKN A2H9WD

Market cap (in EUR)
40,138 m
Country
Netherlands
Sector
Healthcare
Dividend yield
0.00%
 

Overview

Description

argenx SE is a global immunology company, which engages in improving the lives of people suffering from severe autoimmune diseases. It operates through the following geographical segments: United States, Japan, EMEA, and China. The company was founded by Hans J. W. de Haard, Torsten Dreier, and Tim van Hauwermeiren in 2008 and is headquartered in Amsterdam, the Netherlands.
Show more Show less
Healthcare Biopharmaceuticals System-Specific Biopharmaceuticals Netherlands

Financials

Key metrics

Market capitalisation, EUR 40,138 m
EPS, EUR -
P/B ratio 6.5
P/E ratio 36.2
Dividend yield 0.00%

Income statement (2025)

Revenue, EUR 3,693 m
Net income, EUR 1,149 m
Profit margin 31.11%

What ETF is argenx in?

There are 4 ETFs which contain argenx. All of these ETFs are listed in the table below. The ETF with the largest weighting of argenx is the iShares Nasdaq US Biotechnology UCITS ETF USD (Dist).
ETF Weight Investment focus Fund size (in m EUR)
Goldman Sachs Paris-Aligned Climate World Equity UCITS ETF USD (Acc) 0.10%
Equity
World
Social/Environmental
Climate Change
7
iShares Nasdaq US Biotechnology UCITS ETF USD (Dist) 1.69%
Equity
United States
Health Care
Biotech
48
Amundi Prime Eurozone UCITS ETF DR (D) 0.72%
Equity
Europe
85
Amundi Prime Europe UCITS ETF DR (D) 0.38%
Equity
Europe
222
— Data provided by Trackinsight, etfinfo, Xignite Inc., gettex, FactSet and justETF GmbH.

Quotes are either real-time (gettex) or 15 minutes delayed stock exchange quotes or NAVs (daily published by the fund provider). By default, ETF returns include dividend payments (if applicable). There is no warranty for completeness, accuracy and correctness for the displayed information.